Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination penicillin-class antibiotic and beta-lactamase inhibitor. It has broad-spectrum activity against many Gram-positive, Gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin-structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Febrile neutropenia (empiric treatment)
## Adult Dosing
Standard adult dosing is 3.375 grams every 6 hours or 4.5 grams every 6 or 8 hours, administered intravenously. Dosing frequency and duration depend on the indication, severity of infection, and patient response. Higher doses (e.g., 4.5 grams every 6 hours) are often used for more severe infections or when targeting specific pathogens like *Pseudomonas aeruginosa*. For febrile neutropenia, 4.5 grams every 6 hours is common.
## Pediatric Dosing
Dosing in pediatric patients (from birth to 12 years) is weight-based and depends on the indication.
* **For infections other than febrile neutropenia:** 24 mg/kg/hour (piperacillin component) administered via continuous infusion or 80 mg/kg/dose (piperacillin component) every 6 hours administered via intermittent infusion. Maximum dose: 4.5 grams/dose.
* **For febrile neutropenia:** 80 mg/kg/dose (piperacillin component) every 6 hours administered via intermittent infusion. Maximum dose: 4.5 grams/dose.
* **Neonates (0-3 months):** Dosing is highly variable and should be guided by local protocols and expert consultation due to immature renal and hepatic function.
## Dose Adjustments
* **Renal Impairment:** Dose reduction and/or increased interval is necessary for creatinine clearance (CrCl) < 40 mL/min.
* CrCl 20-40 mL/min: 2.25 g or 3.375 g every 8 hours.
* CrCl < 20 mL/min: 2.25 g or 3.375 g every 12 hours.
* Hemodialysis: Administer dose after dialysis session; usual dose is 2.25 g or 3.375 g every 8 hours.
* **Hepatic Impairment:** No specific dose adjustment is typically required.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, or other beta-lactam antibiotics.
* History of severe allergic reaction (e.g., anaphylaxis) to penicillins or cephalosporins.
## Adverse Effects
Common adverse effects include diarrhea, nausea, vomiting, rash, headache, insomnia, and phlebitis at the infusion site. Serious adverse effects can include *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures, and hematologic abnormalities (e.g., eosinophilia, leukopenia).
## Key Drug Interactions
* **Probenecid:** May increase and prolong serum concentrations of piperacillin-tazobactam.
* **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease the effect of warfarin, leading to decreased INR. Monitor INR closely.
* **Methotrexate:** May decrease serum methotrexate levels. Monitor methotrexate levels.
## Monitoring
* Signs and symptoms of infection (fever, WBC count, inflammatory markers).
* Renal function (serum creatinine, CrCl).
* Electrolytes.
* Liver function tests.
* Signs of hypersensitivity reactions.
* For patients on warfarin, monitor INR.
* For patients on methotrexate, monitor methotrexate levels.
## Clinical Pearls
* Piperacillin-tazobactam covers *Pseudomonas aeruginosa*.
* Discontinuation of empiric beta-lactam therapy in neutropenic patients should be based on clinical response and resolution of neutropenia.
* The risk of seizures may be increased in patients with renal impairment.
* Monitor for signs of *C. difficile* infection.
***
**Disclaimer:** This information is intended for clinical professionals. Always verify current prescribing information with the official drug label or a trusted formulary resource before making clinical decisions. Guidelines and recommendations may change.
